nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.02.2010 | Review

Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors

verfasst von: Rebecca Liu, Duane A. Mitchell

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Excerpt

Despite aggressive multi-modality therapy including image-guided surgical resection, maximum external beam radiation therapy, and prolonged cycles of adjuvant chemotherapy, the prognosis for patients diagnosed with malignant brain tumors remains poor [1]. In patients with malignant brain tumors, the normal brain parenchyma is deeply infiltrated by invasive tumor cells. Therefore, treatments that specifically target cancer cells without harming the surrounding normal brain are critically needed. Immunotherapy targeting tumor-specific antigens is a modality that can meet this specificity by taking advantage of the exquisite precision of the human immune system in targeting cells for cytolytic destruction. Currently, studies have demonstrated the feasibility of activating the immune system to eliminate tumors [2], and future efforts are aimed at identifying potential target antigens and maximizing the effectiveness of immunotherapy. Survivin was identified over a decade ago as an inhibitor of apoptosis that promotes tumorigenesis [3], and has been used as an antigenic target for immunotherapy in a variety of cancers such as pancreatic, gastric, and lung cancer [4‐6]. However, immunotherapy efforts targeting survivin in patients with malignant brain tumors are relatively devoid despite considerable rationale for exploitation of this frequently over-expressed tumor antigen. In this review, we have summarized the data supporting the potential of survivin as an immunotherapeutic target antigen for adult and pediatric brain tumors. …

Mitchell DA, Fecci PE, Sampson JH (2008) Immunotherapy of malignant brain tumors. Immunol Rev 222:70–100CrossRefPubMed

Finn OJ (2008) Cancer immunology. N Engl J Med 358(25):2704–2715CrossRefPubMed

Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917–921CrossRefPubMed

Zhu K et al (2007) Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 25(46):7955–7961PubMed

Xiang R et al (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65(2):553–561PubMed

Tu SP et al (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63(22):7724–7732PubMed

Wikstrand CJ et al (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57(18):4130–4140PubMed

Davies H et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954CrossRefPubMed

Andersen MH et al (2004) Immunogenicity of constitutively active V599EBRaf. Cancer Res 64(15):5456–5460CrossRefPubMed

10.

Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49(17):4682–4689PubMed

11.

Simpson AJ et al (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5(8):615–625CrossRefPubMed

12.

Yokoe T et al (2008) Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis. Cancer Res 68(4):1074–1082CrossRefPubMed

13.

Dudley ME et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233–5239CrossRefPubMed

14.

Zhen HN et al (2005) Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104(12):2775–2783CrossRefPubMed

15.

Xie D et al (2006) Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer 94(1):108–114CrossRefPubMed

16.

Takekawa Y, Sawada T, Sakurai I (1999) Expression of apoptosis and its related protein in astrocytic tumors. Brain Tumor Pathol 16(1):11–16CrossRefPubMed

17.

Satoh K et al (2001) Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92(2):271–278CrossRefPubMed

18.

Sasaki T et al (2002) Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol 104(1):105–109CrossRefPubMed

19.

Sarela AI et al (2002) Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 86(6):886–892CrossRefPubMed

20.

Li XN et al (2007) Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol 33(1):67–76CrossRefPubMed

21.

Borriello A et al (2002) Proliferate and survive: cell division cycle and apoptosis in human neuroblastoma. Haematologica 87(2):196–214PubMed

22.

Tamm I et al (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58(23):5315–5320PubMed

23.

Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22(53):8581–8589CrossRefPubMed

24.

Li F et al (1999) Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1(8):461–466CrossRefPubMed

25.

Velculescu VE et al (1999) Analysis of human transcriptomes. Nat Genet 23(4):387–388CrossRefPubMed

26.

Mahotka C et al (1999) Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59(24):6097–6102PubMed

27.

Badran A et al (2004) Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun 314(3):902–907CrossRefPubMed

28.

Caldas H, Honsey LE, Altura RA (2005) Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 4(1):11CrossRefPubMed

29.

Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410CrossRefPubMed

30.

Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18(1):4–25CrossRefPubMed

31.

Kim I et al (2008) Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Circ Res 86(1):24–29

32.

Karsan A et al (1997) Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am J Pathol 151(6):1775–1784PubMed

33.

Gerber HP et al (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273(46):30336–30343CrossRefPubMed

34.

Tran J et al (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99(7):4349–4354CrossRefPubMed

35.

Gerber HP, Dixit V, Ferrara N (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273(21):13313–13316CrossRefPubMed

36.

Zwerts F et al (2007) Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. Blood 109(11):4742–4752CrossRefPubMed

37.

Ma A et al (2007) The role of survivin in angiogenesis during zebrafish embryonic development. BMC Dev Biol 7:50CrossRefPubMed

38.

O’Connor DS et al (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156(2):393–398PubMed

39.

Blanc-Brude OP et al (2003) Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9(7):2683–2692PubMed

40.

Mesri M et al (2001) Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 158(5):1757–1765PubMed

41.

Das A, Tan WL, Smith DR (2003) Expression of the inhibitor of apoptosis protein survivin in benign meningiomas. Cancer Lett 193(2):217–223CrossRefPubMed

42.

Das A et al (2002) Expression of survivin in primary glioblastomas. J Cancer Res Clin Oncol 28(6):302–306CrossRef

43.

Kajiwara Y et al (2003) Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97(4):1077–1083CrossRefPubMed

44.

Kayaselcuk F et al (2004) The expression of survivin and Ki-67 in meningiomas: correlation with grade and clinical outcome. J Neurooncol 67(1–2):209–214CrossRefPubMed

45.

Saito T et al (2007) Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol 82(2):193–198CrossRefPubMed

46.

Chakravarti A et al (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20(4):1063–1068CrossRefPubMed

47.

Katoh M et al (2003) Survivin in brain tumors: an attractive target for immunotherapy. J Neurooncol 64(1–2):71–76PubMed

48.

Heesters MA et al (1999) Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neurooncol 44(3):255–266CrossRefPubMed

49.

Ralte AM et al (2001) Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors. Pathol Oncol Res 7(4):267–278CrossRefPubMed

50.

Yew DT, Wang HH, Zheng DR (1998) Apoptosis in astrocytomas with different grades of malignancy. Acta Neurochir (Wien) 140(4):341–347CrossRef

51.

Nakamizo A et al (2002) Enhanced apoptosis in pilocytic astrocytoma: a comparative study of apoptosis and proliferation in astrocytic tumors. J Neurooncol 57(2):105–114CrossRefPubMed

52.

Jin F et al (2008) Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes. Neuroscience 154(2):541–550CrossRefPubMed

53.

Singh SK et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828PubMed

54.

Fangusaro JR et al (2005) Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 92(2):359–365PubMed

55.

Azuhata T et al (2001) The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg 36(12):1785–1791CrossRefPubMed

56.

Sohn DM et al (2006) Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother 60(6):289–292CrossRefPubMed

57.

Ye CP et al (2007) Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J Gastroenterol 13(46):6264–6268CrossRefPubMed

58.

Azuhata T et al (2006) Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediatr Surg 41(8):1431–1440CrossRefPubMed

59.

Sandler A et al (2002) The survivin:Fas ratio is predictive of recurrent disease in neuroblastoma. J Pediatr Surg 37(3):507–511CrossRefPubMed

60.

Andersen MH et al (2001) Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 61(3):869–872PubMed

61.

Charalambous A et al (2006) Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin. J Immunol 177(12):8410–8421PubMed

62.

Cho HI et al (2007) Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cancer Lett 258(2):189–198CrossRefPubMed

63.

Ciesielski MJ et al (2006) Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 55(12):1491–1503CrossRefPubMed

64.

Idenoue S et al (2005) A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 11(4):1474–1482CrossRefPubMed

65.

Reed JC, Wilson DB (2003) Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9:6523–6533. Clin Cancer Res 9(17):6310–6315

66.

Wobser M et al (2006) Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 55(10):1294–1298CrossRefPubMed

67.

Kim CH et al (2007) Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 122(4):615–622CrossRefPubMed

68.

Yang Z et al (2008) A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency. Mol Immunol 45(6):1674–1681CrossRefPubMed

69.

Pisarev V et al (2003) Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9(17):6523–6533PubMed

70.

Tsuruma T et al (2004) Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2(1):19CrossRefPubMed

71.

Tsuruma T et al (2008) Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 6:24CrossRefPubMed

72.

Zhang T et al (2001) Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61(24):8664–8667PubMed

73.

Fukuda S, Pelus LM (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5(5):1087–1098CrossRefPubMed

74.

Deeg HJ, Huss R (1993) Major histocompatibility complex class II molecules, hemopoiesis and the marrow microenvironment. Bone Marrow Transplant 12(5):425–430PubMed

75.

Serke S, Huhn D (1996) Expression of class I, II and III epitopes of the CD34 antigen by normal and leukemic hemopoietic cells. Cytometry 26(2):154–160CrossRefPubMed

76.

Andersen MH, Becker JC, Straten P (2005) Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 4(5):399–409CrossRefPubMed

Titel: Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors
verfasst von: Rebecca Liu
Duane A. Mitchell
Publikationsdatum: 01.02.2010
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 2/2010
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0757-9

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors

Excerpt

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo)

Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells

Systemic dysregulation of CEACAM1 in melanoma patients

A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer

Tumors induce the formation of suppressor endothelial cells in vivo

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie